Related Experiment Video
Updated: Aug 6, 2026
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
Circulating Protein Biomarkers for Primary Cardiomyopathy: Evidence from Mendelian Randomization and Clinical
Jie He1, Xiaoyan Liu2, Jianhui Tang1
1Department of Cardiology, Jintang County Second People's Hospital, Chengdu, Sichuan, People's Republic of China.
Anatolian Journal of Cardiology
|August 5, 2026
Summary
A new 4-protein panel shows high accuracy in diagnosing primary cardiomyopathy. This panel, including CD163 and LGALS3BP, offers improved diagnostic discrimination for this challenging heart condition.
Area of Science:
- Cardiovascular Genetics
- Proteomics
- Biomarker Discovery
Background:
- Primary cardiomyopathy diagnosis is challenging due to varied symptoms and non-specific biomarkers.
- Existing circulating biomarkers lack specificity for differentiating cardiomyopathy subtypes.
Purpose of the Study:
- To identify and validate mechanism-informed plasma biomarkers for primary cardiomyopathy.
- To evaluate the diagnostic performance of these biomarkers in a clinical setting.
Main Methods:
- Integrated proteome-wide Mendelian randomization (MR) across proteomic and GWAS data.
- Validated top MR candidates using enzyme-linked immunosorbent assays in a case-control cohort.
- Correlated plasma biomarker levels with echocardiographic measures of cardiac function.
Main Results:
- MR prioritized 27 proteins; 5 biomarkers (CD163, LGALS3BP, FABP5, FSTL3, VCAM1) showed significant plasma level differences.
- CD163 and LGALS3BP were identified as independent predictors of cardiomyopathy.
- A 4-protein panel (CD163, LGALS3BP, FABP5, FSTL3) achieved high diagnostic discrimination (AUC 0.988).
Conclusions:
- An integrative genetic-clinical approach identified a 4-protein plasma panel for primary cardiomyopathy diagnosis.
- This panel demonstrates promising diagnostic accuracy and requires external validation.
- CD163 and LGALS3BP are key markers for future research in cardiomyopathy.
Related Concept Videos
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...